CJC-1295 Research: Modified GHRH Analog Peptide

Research Use Only. The information presented here is for scientific and educational purposes. These compounds are not intended for human consumption, self-administration, or therapeutic use.

Introduction

CJC-1295 research investigates a class of modified growth hormone-releasing hormone (GHRH) analog research peptides developed to extend the duration of action of the native GHRH(1-29) fragment. Native human GHRH is a 44-amino-acid hypothalamic peptide that signals through the GHRH receptor (GHRH-R) on anterior pituitary somatotrophs to stimulate pulsatile release of growth hormone (GH). The N-terminal 29 amino acids — the GHRH(1-29) or “sermorelin” fragment — retain full bioactivity, providing the chemistry foundation for an entire class of GHRH analog research peptides.

The principal limitation of unmodified GHRH(1-29) is its very short plasma half-life — approximately 7 minutes — due to rapid degradation by dipeptidyl peptidase-4 (DPP-4) and other plasma peptidases. CJC-1295 in its “No DAC” form, also known as Mod GRF 1-29, incorporates four amino acid substitutions that confer enzymatic stability while preserving GHRH-R agonism. This article reviews the molecular profile, mechanism, and preclinical research domains for CJC-1295 (No DAC), with attention to the broader landscape of GH-axis research peptides and methodological considerations for somatotroph pharmacology research.

Molecular Profile

CJC-1295 No DAC, also termed Mod GRF 1-29, is a 29-amino-acid peptide with the following amino acid substitutions relative to native GHRH(1-29):

• Tyr¹ → D-Ala¹ — confers DPP-4 resistance by preventing N-terminal dipeptide cleavage.
• Ala²⁻⁸ → Gln²⁵, Ala¹⁵ substitutions reduce serine protease susceptibility.
• Leu²⁷ → Ala²⁷ reduces methionine oxidation-related degradation.

The full sequence is H-(D-Ala)-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH₂, with C-terminal amidation. The molecular weight is approximately 3,367 Da.

The full CJC-1295 molecule (sometimes referred to as CJC-1295 with DAC) additionally incorporates a maleimidopropionic acid lysine (the “Drug Affinity Complex” or DAC) that covalently binds plasma albumin, extending half-life to approximately one to two weeks. The “No DAC” form, by contrast, retains the four protease-resistance substitutions but lacks the albumin-binding chemistry, yielding a half-life of approximately 30 minutes — substantially longer than native GHRH(1-29) but short enough to preserve pulsatile GH release dynamics in preclinical research.

The C-terminal amidation is preserved in both CJC-1295 No DAC and native GHRH(1-29) because it is essential for GHRH-R binding affinity. The free C-terminal acid form shows substantially reduced potency in receptor binding assays, illustrating the importance of post-translational modifications in GHRH family pharmacology. Quality control of research-grade CJC-1295 includes mass spectrometric confirmation of the amidated C-terminus and HPLC verification of the absence of deamidation products that can accumulate during synthesis or storage.

Mechanism of Action

CJC-1295 No DAC acts as an agonist at the GHRH receptor (GHRH-R), a class B G protein-coupled receptor expressed primarily on anterior pituitary somatotrophs. GHRH-R activation is Gαs-coupled, elevating intracellular cyclic AMP and triggering somatotroph depolarization, calcium influx, and release of stored GH from secretory granules.

The pulsatile pattern of GH release is one of the defining features of GHRH physiology. Native GHRH is released in episodic bursts from the hypothalamus, producing corresponding pulses of pituitary GH release that are integrated against the inhibitory tone of somatostatin. The relatively short half-life of CJC-1295 No DAC — sufficient to amplify endogenous GH pulses without producing tonic, non-pulsatile receptor activation — has made it a preferred research tool over longer-acting GHRH analogs when investigators want to preserve physiological pulse architecture.

CJC-1295 No DAC is frequently studied in combination with ghrelin/GHS receptor agonist research peptides such as Ipamorelin and GHRP-2, because GHRH-R and GHSR-1a engage distinct intracellular cascades (Gαs vs. Gq/11), producing synergistic GH release in preclinical models that exceeds the effect of either pathway alone.

At the somatotroph level, GHRH-R activation also drives somatotroph proliferation and differentiation, effects that have been characterized in detail in the pituitary development literature. Frohman and Kineman (2002), publishing in Trends in Endocrinology and Metabolism, summarized the role of GHRH signaling in pituitary somatotroph hyperplasia and the implications for chronic GHRH analog research (PMID: 12163233). This mechanistic background is relevant for researchers designing chronic dosing protocols with GHRH analog research peptides.

Key Research Areas

1. GHRH Analog Modifications and Half-Life Extension

The chemistry of GHRH analog peptide design has been extensively characterized in the medicinal chemistry literature. Teichman et al. (2006) reported on a class of GHRH analogs incorporating amino acid substitutions and albumin-binding moieties to extend half-life, providing the framework that underlies the CJC-1295 family of research peptides (PMID: 16352693). The “No DAC” subclass occupies a specific design niche: long enough to permit practical research dosing intervals, short enough to preserve pulsatile GH dynamics.

Sackmann-Sala et al. (2009), publishing in Growth Hormone & IGF Research, characterized the activation of the GH/IGF-1 axis by CJC-1295 in healthy adults, providing pharmacokinetic and serum protein profile data that has informed subsequent preclinical study design (PMID: 19467903). The serum protein profiling work demonstrated that CJC-1295 activates the canonical GH-IGF-1 axis with the expected downstream signatures.

2. Pulsatile GH Release Research

The integrity of pulsatile GH release patterns is biologically important: tonic, non-pulsatile GH exposure produces different downstream effects on hepatic IGF-1 generation, lipolysis, and gene expression than pulsatile exposure. CJC-1295 No DAC’s pharmacokinetic profile — short enough to fall off receptor before the next physiological GH pulse — has made it the preferred GHRH analog research peptide for investigators studying GH pulse amplification rather than sustained elevation.

Ionescu and Frohman (2006), publishing in the Journal of Clinical Endocrinology & Metabolism, documented that pulsatile GH secretion is preserved during continuous CJC-1295 stimulation, providing the critical demonstration that long-acting GHRH analog research peptides do not necessarily abolish endogenous pulse architecture (PMID: 16968795). This finding has been foundational for the design of chronic GHRH analog dosing protocols in preclinical somatotroph research.

3. Combination Research with GH Secretagogues

The synergistic relationship between GHRH-R and GHSR-1a engagement has been characterized in multiple preclinical models. Bowers and colleagues demonstrated decades ago that GHRH and GHS compounds produce additive-to-synergistic GH release when co-administered, owing to their non-overlapping intracellular cascades. CJC-1295 No DAC paired with selective GHS research peptides such as Ipamorelin represents the most commonly studied combination paradigm in this literature. Pre-combined research material is also available as a CJC-1295 + Ipamorelin blend.

Bowers (2001), publishing in the Journal of Clinical Endocrinology & Metabolism, summarized the conceptual framework for combining GHRH and GHS research peptides, including the receptor-pharmacology rationale for additive-to-synergistic effects (PMID: 11297569). Veldhuis and Bowers (2010) extended this framework in the International Journal of Peptides, providing a comprehensive treatment of GHS integration into the ghrelin system (PMID: 20798846).

4. Body Composition and Anabolic Endpoints

Preclinical research in rodent and pediatric-relevant animal models has examined GHRH analog research peptides for effects on body composition through GH/IGF-1 axis engagement. The downstream consequences of repeated GH pulse amplification include increased hepatic IGF-1 production, lipolytic activity in adipose tissue, and anabolic signaling in skeletal muscle and bone — effects that are characteristic of the broader GH-releasing peptide class and that have been documented for related research peptides including Sermorelin and Tesamorelin.

Mayo et al. (2003), publishing in Pharmacological Reviews, provided the IUPHAR classification and pharmacological characterization of the glucagon receptor family, including the GHRH receptor as a class B GPCR, with detailed treatment of receptor selectivity and signaling (PMID: 12615957).

Comparative Research Landscape

CJC-1295 No DAC occupies a specific niche within the broader landscape of GH-axis research peptides. The GHRH analog class includes the native fragment Sermorelin (unmodified GHRH 1-29), Tesamorelin (a stabilized GHRH(1-44) analog), CJC-1295 No DAC (the four-substitution Mod GRF 1-29), and CJC-1295 with DAC (the same molecule plus albumin-binding chemistry). These compounds span a pharmacokinetic range from minutes (sermorelin) to days (CJC-1295 with DAC), allowing researchers to select duration of action appropriate to the experimental question.

The GH secretagogue (GHS) class — engaging the GHSR-1a receptor rather than GHRH-R — includes Ipamorelin (highly selective), GHRP-2 (with measurable cortisol and prolactin co-stimulation), GHRP-6, and hexarelin. Combination protocols pairing GHRH analog research peptides with GHS research peptides exploit the non-overlapping receptor cascades to produce additive-to-synergistic GH release that exceeds the effect of either pathway alone.

Researchers selecting among these classes typically weigh four considerations: the desired duration of receptor engagement (favoring CJC-1295 No DAC for pulse-preserving protocols and CJC-1295 with DAC for sustained engagement), receptor pathway (GHRH-R vs. GHSR-1a), selectivity at adjacent endocrine axes (favoring Ipamorelin over GHRP-2 when cortisol/prolactin confounds matter), and the cost-per-active-dose for the experimental scale. Combination CJC-1295 No DAC + Ipamorelin protocols have become the most commonly studied configuration in the modern GH-axis preclinical literature.

Research Methodology Considerations

Cell-based GHRH-R activation assays typically use HEK293 or CHO cells stably transfected with human GHRH-R, with cyclic AMP accumulation as the principal functional readout. Rat pituitary primary cell cultures and GH3 cell lines (a rat pituitary tumor-derived line that expresses GHRH-R) are used for more physiologically relevant somatotroph pharmacology research, with GH secretion into the medium quantified by ELISA or radioimmunoassay.

In vivo characterization in rodent models typically uses subcutaneous CJC-1295 No DAC administration with serial blood sampling for serum GH measurement at 5-, 15-, 30-, 60-, 120-, and 240-minute time points to capture pulse dynamics. IGF-1 measurement at 24 hours post-dose provides an integrated marker of GH-axis engagement. Combination protocols with GHS research peptides require careful attention to the order and timing of administration because the synergistic interaction is most pronounced when both compounds engage their receptors within the same somatotroph response window.

Common methodological pitfalls include underestimating the contribution of endogenous somatostatin tone, which can substantially blunt CJC-1295 effects in conscious animal preparations relative to anesthetized or somatostatin-depleted models. Diurnal variation in baseline GH secretion is another common confounder; researchers typically standardize sampling time relative to the light-dark cycle. Characterization standards for research-grade CJC-1295 No DAC include peptide identity by mass spectrometry, greater than or equal to 98% purity by analytical HPLC, confirmation of C-terminal amidation, and verification of the D-Ala1 substitution that distinguishes the compound from native GHRH(1-29).

Pharmacokinetics and Bioavailability Considerations

The pharmacokinetic profile of CJC-1295 No DAC is shaped by the four protease-resistance substitutions that confer modest stability against DPP-4 and other plasma peptidases. Following subcutaneous administration in rodent species, the molecule shows a terminal half-life of approximately 30 minutes — substantially longer than the 7-minute half-life of native GHRH(1-29) but markedly shorter than the 1-2 week half-life of CJC-1295 with DAC. This intermediate pharmacokinetic profile is the principal pharmacological distinction of the No DAC form and is the basis for its preferred use in pulse-architecture-sensitive research.

Tissue distribution of administered CJC-1295 No DAC reaches the anterior pituitary somatotroph population that expresses GHRH-R, with measurable receptor engagement and GH release within minutes of administration. The compound modest plasma protein binding distinguishes it from albumin-bound long-acting analog research peptides. Renal clearance and proteolytic degradation both contribute to the overall clearance profile.

For combination protocols with GH secretagogue research peptides such as Ipamorelin or GHRP-2, the relatively rapid clearance of CJC-1295 No DAC supports near-simultaneous administration with the GHS compound to maximize receptor co-engagement at the somatotroph population. Researchers designing such protocols typically administer both compounds within minutes of each other to ensure synergistic Gαs and Gq/11 signaling at the same somatotroph response window.

Plasma concentration measurement is typically performed by validated immunoassay or LC-MS/MS, with attention to potential cross-reactivity with endogenous GHRH in immunoassay formats. The D-Ala1 substitution may affect epitope recognition in some immunoassay configurations, requiring method validation specific to the No DAC form.

Translational Research Context

The translational research context for CJC-1295 No DAC has been shaped by the broader development of GH-axis research peptides over more than three decades. The recognition that GHRH analog peptides can amplify pulsatile GH release without disrupting the underlying pulse architecture has positioned CJC-1295 No DAC as a preferred tool for investigating GH pulse dynamics in preclinical models. The combination of this pulse-preserving pharmacokinetic profile with the well-characterized GHRH-R pharmacology has supported a substantial body of preclinical research on body composition, anabolic signaling, and combination GHRH/GHS protocols.

Beyond GH-axis research, the broader landscape of secretagogue and analog peptide research has been informed by the methodological insights developed in the CJC-1295 No DAC literature. The careful attention to pulse architecture, the systematic comparison of long-acting versus short-acting analog forms, and the rigorous combination-protocol design with non-overlapping receptor cascades all represent transferable methodological frameworks for other peptide hormone research areas.

The relationship to IGF-1 axis research is also worth emphasizing. CJC-1295 No DAC effects on serum IGF-1 reflect the downstream consequences of GH pulse amplification and provide an integrated readout of GH-axis engagement. Researchers using direct IGF-1 analog research peptides such as IGF-1 LR3 often pair these comparator studies with CJC-1295 No DAC to distinguish GH-mediated from IGF-1-direct effects in muscle, bone, and metabolic research contexts.

Research Considerations for Laboratory Use

Research-grade CJC-1295 No DAC should be supplied as a lyophilized powder at a purity standard of greater than or equal to 98% by HPLC, with a Certificate of Analysis documenting peptide content, identity by mass spectrometry, and impurity profile. The lyophilized form is typically stored at -20 degrees C and is stable for extended periods when sealed and protected from moisture.

For reconstitution in research protocols, bacteriostatic water (0.9% benzyl alcohol) or sterile 0.9% saline are commonly used. Reconstituted peptide solutions should be stored at 2-8 degrees C and used within a defined window to minimize aggregation or degradation. Investigators should verify concentration spectrophotometrically and follow institutional animal-care protocols for any in vivo research applications.

Conclusion

CJC-1295 No DAC (Mod GRF 1-29) is a 29-amino-acid GHRH analog research peptide whose four protease-resistance substitutions extend plasma half-life enough to permit practical research dosing intervals while preserving the pulsatile GH release dynamics that distinguish GHRH-R agonism from longer-acting albumin-bound analogs. Its position as a GHRH-class research peptide complements the GH secretagogue class — GHSR-1a agonists such as ipamorelin and GHRP-2 — and the two are commonly studied in combination preclinical protocols.

The findings described here are derived from in vitro and animal model contexts. They do not constitute therapeutic claims, and translational extrapolation to human use requires dedicated clinical investigation. Researchers working with CJC-1295 No DAC should design studies aligned with institutional protocols and applicable regulations.

The continued role of CJC-1295 No DAC as a foundational GHRH analog research tool reflects the careful design choices that distinguish it from longer-acting alternatives: short enough to permit pulse-preserving research protocols, long enough to support practical experimental dosing intervals. CJC-1295 No DAC will likely continue to serve as an essential GHRH-axis tool compound for the foreseeable future.

References

1. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PMID: 16352693.
2. Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009;19(6):471-477. PMID: 19467903.
3. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. PMID: 16968795.
4. Bowers CY. Unnatural growth hormone-releasing peptide begets natural ghrelin. J Clin Endocrinol Metab. 2001;86(4):1464-1469. PMID: 11297569.
5. Veldhuis JD, Bowers CY. Integrating GHS into the ghrelin system. Int J Pept. 2010;2010:879503. PMID: 20798846.
6. Mayo KE, Miller T, Bataille D, et al. International Union of Pharmacology. XXXV. The glucagon receptor family. Pharmacol Rev. 2003;55(1):167-194. PMID: 12615957.
7. Frohman LA, Kineman RD. Growth hormone-releasing hormone and pituitary development, hyperplasia and tumorigenesis. Trends Endocrinol Metab. 2002;13(7):299-303. PMID: 12163233.
8. Mayo KE. Molecular cloning and expression of a pituitary-specific receptor for growth hormone-releasing hormone. Mol Endocrinol. 1992;6(10):1734-1744. PMID: 1333056.
9. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PMID: 9849822.
10. Frohman LA, Jansson JO. Growth hormone-releasing hormone. Endocr Rev. 1986;7(3):223-253. PMID: 3098562.